Biosimilars

The new model will test a new way to lower increasing drug prices for patients paying for drugs under Medicare Part B.

How will biosimilars continue to affect the prescription product market in 2021?

The advent of generic and biosimilar medicines for novel treatments has helped bridge the gap in the delivery of cancer care between the United States and India, according to the study.

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

Biosimilar to Remicade

Expected U.S. launch in 2023.

Biosimilars may need more time to devleop in the market.

Biologic medicines could lower spending by $153 billion by 2023.

New changes are making it more difficult for generics and biosimilars to compete on formularies.

CD20-directed antibody indicated for several cancers and other conditions.

Biosimilar guidance provides “clarity” for drug developers.

Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma. 

Only new biosimilars and interchangeables will recieve four-letter suffixes.

The report by Magellan Rx Management indicates PMPM, site of service, and Medicaid prices continue to increase. 

Specialty pharmaceuticals make up a significant part of the current drug market, and their impact is only going to grow over the next few years.

Stalled competition hurts consumers and may keep prices higher.

Drug Topics recently spoke with the FDA about the role pharmacists can play in patient education.

The annual report on generic access and savings shows some impressive numbers for 2017.

An unclear naming system for biosimilars could affect patient safety.

FDA releases Biosimilar Action Plan